What is Orkambi, and what approvals is it associated with?
Orkambi is a cystic fibrosis (CF) medicine that received regulatory approval for certain people with CF. Specifically, it was approved for patients who have cystic fibrosis due to two copies of the F508del mutation (homozygous F508del), the mutation targeted by the drug’s mechanism. [1]
What does “approval” mean for Orkambi in practice?
When people search “Orkambi and approval,” they often mean which regulator approved it, for which patient group, and under what conditions (such as the mutation type). In the material available here, the core approval detail is the F508del mutation requirement (homozygous F508del). [1]
Who is it approved for (mutation/eligibility angle)?
Orkambi’s approval is tied to CF patients with cystic fibrosis caused by homozygous F508del mutations. If a patient has CF but does not meet that mutation pattern, Orkambi may not fit the approved indication described in the available source. [1]
Which regulator approved Orkambi?
The provided information does not specify which country/agency approved Orkambi, but it does connect the approval decision to the patient’s F508del genotype eligibility. [1]
Can patients with different mutations get Orkambi even if they weren’t in the approved indication?
Based on the approval detail available here, eligibility is defined by homozygous F508del status. Patients outside that mutation group would need to rely on different approved CFTR modulators (or a different indication/label) rather than assuming Orkambi approval applies broadly. [1]
Sources
1. https://www.drugs.com/medicine/orkambi.html